2016 American Transplant Congress
Understanding the Initial Rise in Kidney Discard Rates Observed Post-KAS.
1UNOS, Richmond, VA; 2Emory Univ, Atlanta, GA; 3Univ Hosp Case Med Ctr, Cleveland, OH.
Background: Kidney discard rates increased by 10% -- from 18.3% to 20.2% (p=0.001) -- during the first 7 months of KAS but returned to pre-KAS…2016 American Transplant Congress
99% and 100% CPRA Patients Since KAS: A Substantial Increase in Transplants with Strong Evidence of a Bolus Effect.
1UNOS, Richmond, VA; 2Univ Hosp Case Med Ctr, Cleveland, OH; 3Emory Univ Hosp, Atlanta, GA.
Background: The Kidney Allocation System (KAS), implemented on 12/4/14, increased allocation priority for candidates with CPRA of 99-100%. Analyses performed on behalf of the OPTN…2016 American Transplant Congress
A Pathway to Belatacept Monotherapy: Alemtuzumab, Belatacept and Rapamycin for Kidney Transplantation.
1Emory Transplant Center, Atlanta, GA; 2Duke University, Durham, NC.
Kidney transplantation remains limited by toxicities of calcineurin inhibitors (CNIs) and steroids. Belatacept is a less toxic CNI alternative delivered by monthly intravenous infusion, but…2016 American Transplant Congress
Better Never Than Late: Differences in Outcomes and Risk Factors for Early and Late Rejection After Kidney Transplantation.
Medicine, University Hospitals Case Medical Center, Cleveland, OH.
Background: Late acute rejection (AR) is associated with inferior outcomes relative to early AR after kidney transplantation. We sought to examine the differences in risk…2016 American Transplant Congress
Is C3d-fixing Donor Specific HLA Antibody Detection Really Necessary?
Introduction: Chronic antibody–mediated rejection is the main cause of late kidney graft loss. The identification of donor-specific antibodies (DSA) in the serum is one of…2016 American Transplant Congress
Implications of Subclinical Borderline Acute Cellular Rejection Detected in Protocol Biopsies on Graft Outcomes.
Background: The effects of subclinical borderline acute cellular rejection (BACR-defined as I1T1 per Banff criteria) detected in protocol biopsies (Bx) on subsequent graft function and…2016 American Transplant Congress
Global Kidney Exchange.
Introduction: Instead of thinking of the developing world as a place where there are desperate people who will sell their kidneys for money, we propose…2016 American Transplant Congress
Angiotensin II Type-1 Receptor Antibodies in Renal Transplant Recipients Associated with Ventricular and Endothelial Dysfunction: Preliminary Results.
Previous studies demonstrated the significance of angiotensin II type-1 receptor antibodies (AT1Rabs) in processes including hypertension, cardiac hypertrophy and renal fibrosis; information regarding ventricular and…2016 American Transplant Congress
End-Stage Renal Disease Does Not Impair the Large-Scale Generation of Potent Alloantigen-Specific Regulatory T Cells for Immunotherapy.
Background Alloantigen-specific natural occurring regulatory T cells (nTregs) have the potential to offer a more targeted approach of immunosuppression and are the cell type of…2016 American Transplant Congress
Donor HLA Specific IgM Antibody Measured on Day 14 Post-Transplantation Predicts Poor Graft Survival in HLA-Incompatible Renal Transplantation.
Introduction: Role of IgG antibodies against donor human leucocyte antigens (HLA) is established in renal transplant monitoring. Role of IgM donor HLA specific antibodies (DSA)…
- « Previous Page
- 1
- …
- 419
- 420
- 421
- 422
- 423
- …
- 531
- Next Page »